NCT00424632View on ClinicalTrials.gov

Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Solid Tumors
Interventions
DRUG

PF-03814735

1, 5, and 25 mg gelatin capsules administered orally once a day from day 1 to day 5, or from day 1 to day 10 every 3 weeks until disease progression or unacceptable toxicity.

Trial Locations (2)

3000

Pfizer Investigational Site, Leuven

37203

Pfizer Investigational Site, Nashville

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY